The Center for Genomic Interpretation and NSGC want payors to cover confirmatory testing for patients with positive results from 23andMe's FDA-cleared test.
UnitedHealthcare announced a new lab partnership with Quest, while LabCorp said it will become a preferred national lab for Aetna.
CMS will reimburse FoundationOne CDx at a rate of $3,500 per test for a nine-month period starting July 1.
The company presented new data on the PGx test this week and expressed confidence that they can secure broader payor coverage for it.
The coverage decisions follow similar decisions by Blue Shield of California and First Coast Service Options last year.
PriorAuthNow's platform will be integrated with Xifin RPM 9's intelligent automation. According to Xifin, $31 billion is spent each year on prior authorizations.
The payor published positive medical policy coverage for the ThyGenX and ThyraMir assays for thyroid nodules deemed indeterminate by standard cytopathological analysis.
The final determination also adds coverage for FDA-approved tests in stage III patients, and for repeat testing if patients receive a new primary diagnosis.
The lab industry's appeal to CMS follows Missouri's Medicaid agency's reduction of lab reimbursements from 100 percent to 80 percent of Medicare rates.
Interpace said that its two thyroid tests are now covered for over 280 million patients nationwide including Medicare, Medicare Advantage, and national and regional health plans.